LIVIVO - Search results -

Search results

Result 1 - 8 of total 8

Search options

Article ; Online: Ribociclib-induced hepatotoxicity.

Er, Muhammed Muhiddin / Araz, Murat / Hendem, Engin / Eryılmaz, Melek Karakurt / Artaç, Mehmet

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners

2023 Volume 29, Issue 5, Page(s) 1275–1277

Abstract: Introduction: Cyclin-dependent kinase (CDK) 4/6 inhibitors have shown a different adverse effect. In this case, persistent grade 3 hepatoxicity was observed after ribociclib. Therefore, ribociclib therapy was stopped, and then palbociclib was introduced. ...

Abstract	Introduction: Cyclin-dependent kinase (CDK) 4/6 inhibitors have shown a different adverse effect. In this case, persistent grade 3 hepatoxicity was observed after ribociclib. Therefore, ribociclib therapy was stopped, and then palbociclib was introduced. Transaminase levels returned to normal by switching to palbociclib therapy. Case report: 71-year-old postmenopausal female patient with luminal subtypes of metastatic breast cancer treated with ribociclib. Management & outcome: Grade 3 hepatotoxicity secondary to ribociclib developed. She was successfully treated with palbociclib 125 mg. Discussion: In our case, palbociclib was started with a full dose, to increase treatment success. Starting with a 125 mg dose was not cause any toxicity. Nevertheless, laboratory follow-up is required in terms of neutropenia and increased transaminases.
MeSH term(s)	Female ; Humans ; Aged ; Aminopyridines/adverse effects ; Purines/adverse effects ; Breast Neoplasms/drug therapy ; Breast Neoplasms/pathology ; Drug-Related Side Effects and Adverse Reactions/drug therapy ; Chemical and Drug Induced Liver Injury/etiology ; Chemical and Drug Induced Liver Injury/drug therapy ; Protein Kinase Inhibitors/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use
Chemical Substances	ribociclib (TK8ERE8P56) ; Aminopyridines ; Purines ; Protein Kinase Inhibitors
Language	English
Publishing date	2023-02-10
Publishing country	England
Document type	Case Reports ; Journal Article
ZDB-ID	1330764-2
ISSN	1477-092X ; 1078-1552
ISSN (online)	1477-092X
ISSN	1078-1552
DOI	10.1177/10781552231154009
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 4488: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: The effect of concomitant beta-blocker use on survival in patients with metastatic renal cell carcinoma treated with a vascular endothelial growth factor receptor inhibitors in the first line.

Korkmaz, Mustafa / Eryılmaz, Melek Karakurt / Koçak, Mehmet Zahid / Er, Muhammed Muhiddin / Hendem, Engin / Demirkıran, Aykut / Araz, Murat / Artaç, Mehmet

European journal of clinical pharmacology

2024 Volume 80, Issue 6, Page(s) 941–947

Abstract: Purpose: Vascular endothelial growth factor (VEGF) inhibition is one of the cornerstones of treatment in the treatment of metastatic renal cell carcinoma (mRCC). Since RCC is a disease of advanced age and hypertension as a side effect of VEGF receptor ... ...

Abstract	Purpose: Vascular endothelial growth factor (VEGF) inhibition is one of the cornerstones of treatment in the treatment of metastatic renal cell carcinoma (mRCC). Since RCC is a disease of advanced age and hypertension as a side effect of VEGF receptor inhibitors, beta-blocker use is common in these patients. We aimed to compare the treatment efficacy and survival results in case of concomitant use of these two drugs due to the inhibition of VEGF in beta-blockers. Methods: A total of 121 patients with a diagnosis of mRCC who used sunitinib or pazopanib in first-line therapy were included in the study. These patients were divided into two groups as those using concomitant beta-blockers and those not using them. Result: The median overall survival (mOS) of the patient using sunitinib or pazopanib and concomitant beta-blocker was 47 (95% CI 29.0-65.0) months, and the mOS of those not using concomitant beta-blocker was 18 (95% CI 8.9-27.1) months (p < 0.001). The median progression-free survival (mPFS) of the patients using sunitinib or pazopanib and concomitant beta-blocker was 20.4 (95% CI 4.5-40.1) months, and the mPFS of those not using it was 11.4 (95% CI 5.9-16.9) months (p = 0.042). Concomitant beta-blocker use was found to be a good prognostic factor for OS in the multivariate analysis (p = 0.029). In the multivariate analysis, concomitant beta-blocker use had a trend towards statistical significance for PFS (p = 0.062). Conclusion: Concomitant use of betablockers with sunitinib or pazopanib is associated with longer overall survial and progression free survival.
MeSH term(s)	Humans ; Carcinoma, Renal Cell/drug therapy ; Carcinoma, Renal Cell/mortality ; Indazoles/therapeutic use ; Indazoles/adverse effects ; Indazoles/administration & dosage ; Male ; Female ; Kidney Neoplasms/drug therapy ; Kidney Neoplasms/mortality ; Kidney Neoplasms/pathology ; Sunitinib/therapeutic use ; Middle Aged ; Aged ; Sulfonamides/therapeutic use ; Sulfonamides/administration & dosage ; Sulfonamides/adverse effects ; Pyrimidines/therapeutic use ; Pyrimidines/adverse effects ; Pyrimidines/administration & dosage ; Adrenergic beta-Antagonists/therapeutic use ; Receptors, Vascular Endothelial Growth Factor/antagonists & inhibitors ; Progression-Free Survival ; Adult ; Aged, 80 and over ; Retrospective Studies ; Antineoplastic Agents/therapeutic use ; Antineoplastic Agents/adverse effects
Chemical Substances	pazopanib
Language	English
Publishing date	2024-03-13
Publishing country	Germany
Document type	Journal Article
ZDB-ID	121960-1
ISSN	1432-1041 ; 0031-6970
ISSN (online)	1432-1041
ISSN	0031-6970
DOI	10.1007/s00228-024-03668-8
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 672: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Is the Prognostic Nutritional Index a Prognostic Marker for the Survival of Patients with Lymph-Node Positive Stage II-III Gastric Cancer Who Receive Adjuvant Chemotherapy?

Korkmaz, Mustafa / Eryılmaz, Melek Karakurt / Er, Muhammed Muhiddin / Koçak, Mehmet Zahid / Demirkıran, Aykut / Karaağaç, Mustafa / Araz, Murat / Artaç, Mehmet / Koçak, Zahid Mehmet

Journal of gastrointestinal cancer

2023 Volume 54, Issue 3, Page(s) 962–969

Abstract: Purpose: The prognostic nutritional index (PNI), like other systemic inflammatory markers, has been shown to be a prognostic factor in various cancer patients. In this study, we aimed to show whether PNI calculated before adjuvant chemotherapy is a ... ...

Abstract	Purpose: The prognostic nutritional index (PNI), like other systemic inflammatory markers, has been shown to be a prognostic factor in various cancer patients. In this study, we aimed to show whether PNI calculated before adjuvant chemotherapy is a prognostic factor for overall survival (OS) and disease-free survival (DFS) in patients with lymph node-positive stage II-III gastric cancer. Methods: The PNI was calculated using the albumin and lymphocyte count. The PNI cut-off value was found to be 39.5. They were divided into two groups as being ≤ 39.5 (PNI low group) and > 39.5 (PNI high group). Results: Our study included 168 patients with lymph node-positive stage II-III gastric cancer who received adjuvant chemotherapy. Of the patients, 116 (69.0%) were 65 years or younger, and 52 (31.0%) were over 65 years old. Of the patients, 117 (69.6%) were pT3, 51 (30.4%) were pT4. Seventy-three (43.4%) patients had pN1-2 disease and 95 (56.6%) patients had pN3 disease. The number of stage II patients was 73 (43.5%) and the number of stage III patients was 95 (56.5%). There were 73 patients with PNI ≤ 39.5 and 95 patients with PNI > 39.5. The mOS of the patients with low PNI group was 39.5 months, while the OS of the patients with high PNI group was 96.8 months (p = 0.002). In the group of patients with PNI low group, mDFS 24.4 months was significantly higher than those with PNI high group was 50.7 months (p = 0.021). The PNI score was statistically significant in univariate and multivariate analyzes for both DFS and OS. Conclusion: PNI can be used as an independent prognostic factor for both OS and DFS in patients lymph node-positive, stage II-III gastric cancer who will receive adjuvant chemotherapy.
MeSH term(s)	Humans ; Aged ; Nutrition Assessment ; Stomach Neoplasms/drug therapy ; Prognosis ; Nutritional Status ; Retrospective Studies ; Chemotherapy, Adjuvant
Language	English
Publishing date	2023-09-22
Publishing country	United States
Document type	Journal Article
ZDB-ID	2452514-5
ISSN	1941-6636 ; 1559-0739 ; 1941-6628 ; 1537-3649
ISSN (online)	1941-6636 ; 1559-0739
ISSN	1941-6628 ; 1537-3649
DOI	10.1007/s12029-023-00972-x
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 2184: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Pazopanib-associated secondary adrenal insufficiency in a patient with malignant solitary fibrous tumor.

Er, Muhammed Muhiddin / Araz, Murat / Karabacak, Meryem / Uğraklı, Muzaffer / Eryılmaz, Melek Karakurt / Karaağaç, Mustafa / Artaç, Mehmet

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners

2021 Volume 27, Issue 8, Page(s) 2049–2052

Abstract: Introduction: Pazopanib is an agent that is being successfully used in soft tissue sarcomas. Some endocrine side effects may develop during pazopanib treatment. Here, we presented a case diagnosed with secondary adrenal insufficiency while being ... ...

Abstract	Introduction: Pazopanib is an agent that is being successfully used in soft tissue sarcomas. Some endocrine side effects may develop during pazopanib treatment. Here, we presented a case diagnosed with secondary adrenal insufficiency while being investigated for etiology of hypoglycemia which developed after pazopanib. Case report: A 69-year-old male patient was operated in June 2019 due to a lung mass 26 × 18 × 10 cm in size. Pathological diagnosis revealed a solitary fibrous tumor with malignant behavior. The patient received three lines of chemotherapy. After pazopanib treatment, a hypoglycemic attack was reported. Discussion: A single case of primary adrenal insufficiency has been reported in the literature. We here present a case who developed hypoglycemia after pazopanib and was diagnosed with drug-associated secondary adrenal insufficiency. When hypoglycemia develops during pazopanib treatment, we must be aware of adrenal insufficiency.
MeSH term(s)	Adrenal Insufficiency/chemically induced ; Aged ; Humans ; Indazoles ; Male ; Pyrimidines/adverse effects ; Solitary Fibrous Tumors/chemically induced ; Sulfonamides
Chemical Substances	Indazoles ; Pyrimidines ; Sulfonamides ; pazopanib (7RN5DR86CK)
Language	English
Publishing date	2021-05-12
Publishing country	England
Document type	Case Reports ; Journal Article
ZDB-ID	1330764-2
ISSN	1477-092X ; 1078-1552
ISSN (online)	1477-092X
ISSN	1078-1552
DOI	10.1177/10781552211016081
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 4488: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: The effect of concomitant proton pump inhibitor use on survival outcomes of Nivolumab-treated renal cell carcinoma patients: a multicenter study.

Uğraklı, Muzaffer / Koçak, Mehmet Zahid / Dinç, Gülhan / Genç, Tuğrul Burak / Çağlayan, Melek / Uğraklı, Selin / Hendem, Engin / Er, Muhammed Muhiddin / Çağlayan, Dilek / Eryılmaz, Melek Karakurt / Araz, Murat / Geredeli, Çağlayan / Tatlı, Ali Murat / Eren, Orhan Önder / Artaç, Mehmet

Journal of cancer research and clinical oncology

2023 Volume 149, Issue 11, Page(s) 9183–9189

Abstract: Aim: We aimed to evaluate the effect of concomitant proton pump inhibitors (PPI) use with nivolumab on survival outcomes in metastatic renal cell carcinoma (mRCC) in second-line setting.: Methods: The study was designed as a multicenter and ... ...

Abstract	Aim: We aimed to evaluate the effect of concomitant proton pump inhibitors (PPI) use with nivolumab on survival outcomes in metastatic renal cell carcinoma (mRCC) in second-line setting. Methods: The study was designed as a multicenter and retrospective involving patients with metastatic renal cell carcinoma receiving second-line nivolumab therapy. One hundred and nine patients with mRCC were divided into two groups based on whether they use PPI concomitantly with nivolumab: concomitant PPI users and non-users. Overall survival (OS) and progression-free survival (PFS) were compared between the groups with and without concurrent PPIs. Results: Of 109 patients in our study, 59 were not using PPI concomitantly with nivolumab and 50 were using PPI concomitantly. The median PFS was 6.37 (5.2-7.5) months in the concomitant PPI group and 9.7 (4.5-15) months in the non-users (p = 0.03). The median OS was 14.6 (7.1-22.1) months in patients on PPI concurrently with nivolumab and 29.9 (17.1-42.7) months in the non-users (p = 0.01). Accordingly, PPI use for PFS (Non-use vs. Use = HR: 0.44, 95%Cl 0.28-0.96, p = 0.014) and PPI use for OS (Non-use vs. Use = HR: 0.68, 95%Cl 0.22-0.88, p = 0.01) were found to be as independent risk factors. Conclusions: Concomitant use of PPIs is associated with worse survival outcomes in patients with mRCC treated with nivolumab. Clinicians should carefully consider the concomitant use of PPIs in such patients.
MeSH term(s)	Humans ; Carcinoma, Renal Cell/pathology ; Nivolumab ; Proton Pump Inhibitors/therapeutic use ; Kidney Neoplasms/drug therapy ; Retrospective Studies
Chemical Substances	Nivolumab (31YO63LBSN) ; Proton Pump Inhibitors
Language	English
Publishing date	2023-05-15
Publishing country	Germany
Document type	Multicenter Study ; Journal Article
ZDB-ID	134792-5
ISSN	1432-1335 ; 0171-5216 ; 0084-5353 ; 0943-9382
ISSN (online)	1432-1335
ISSN	0171-5216 ; 0084-5353 ; 0943-9382
DOI	10.1007/s00432-023-04844-6
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Uh III Zs.10: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Treatment outcomes and prognostic factors in patients with driver mutant non-small cell lung cancer and de novo brain metastases.

Kahraman, Seda / Karakaya, Serdar / Kaplan, Muhammed Ali / Goksu, Sema Sezgin / Ozturk, Akin / Isleyen, Zehra Sucuoglu / Hamdard, Jamshid / Yildirim, Sedat / Dogan, Tolga / Isik, Selver / Celebi, Abdussamet / Gulbagci, Burcu Belen / Paksoy, Nail / Dogan, Mutlu / Turk, Haci Mehmet / Bilici, Ahmet / Tatli, Ali Murat / Akbas, Sinem / Turan, Nedim /

Hacibekiroglu, Ilhan / Dogu, Gamze Gokoz / Aydiner, Adnan / Sumbul, Ahmet Taner / Akyurek, Serap / Yalciner, Merih / Demirkazik, Ahmet / Gursoy, Pinar / Aykan, Musa Baris / Sahin, Elif / Karadag, İbrahim / Kostek, Osman / Er, Muhammed Muhiddin / Artaç, Mehmet / Duzkopru, Yakup / Aydin, Dincer / Isik, Deniz / Karakas, Yusuf / Kilickap, Saadettin / Erol, Cihan / Demir, Bilgin / Civelek, Burak / Ergun, Yakup / Akinci, Muhammed Bulent / Dogan, Izzet / Karadurmus, Nuri / Yumuk, Perran Fulden / Sendur, Mehmet Ali Nahit

Scientific reports

2024 Volume 14, Issue 1, Page(s) 5820

Abstract: Central nervous system (CNS) metastases can be seen at a rate of 30% in advanced stages for patients with non-small cell lung cancer (NSCLC). Growing evidence indicates the predictive roles of driver gene mutations in the development of brain metastases ( ...

Abstract	Central nervous system (CNS) metastases can be seen at a rate of 30% in advanced stages for patients with non-small cell lung cancer (NSCLC). Growing evidence indicates the predictive roles of driver gene mutations in the development of brain metastases (BM) in recent years, meaning that oncogene-driven NSCLC have a high incidence of BM at diagnosis. Today, 3rd generation targeted drugs with high intracranial efficacy, which can cross the blood-brain barrier, have made a positive contribution to survival for these patients with an increased propensity to BM. It is important to update the clinical and pathological factors reflected in the survival with real-life data. A multi-center, retrospective database of 306 patients diagnosed with driver mutant NSCLC and initially presented with BM between between November 2008 and September 2022 were analyzed. The median progression-free survival (mPFS) was 12.25 months (95% CI, 10-14.5). While 254 of the patients received tyrosine kinase inhibitor (TKI), 51 patients received chemotherapy as first line treatment. The median intracranial PFS (iPFS) was 18.5 months (95% CI, 14.8-22.2). The median overall survival (OS) was 29 months (95% CI, 25.2-33.0). It was found that having 3 or less BM and absence of extracranial metastases were significantly associated with better mOS and iPFS. The relationship between the size of BM and survival was found to be non-significant. Among patients with advanced NSCLC with de novo BM carrying a driver mutation, long-term progression-free and overall survival can be achieved with the advent of targeted agents with high CNS efficacy with more conservative and localized radiotherapy modalities.
MeSH term(s)	Humans ; Carcinoma, Non-Small-Cell Lung/drug therapy ; Carcinoma, Non-Small-Cell Lung/genetics ; Lung Neoplasms/drug therapy ; Lung Neoplasms/genetics ; Prognosis ; Retrospective Studies ; ErbB Receptors/genetics ; Treatment Outcome ; Brain Neoplasms/drug therapy ; Brain Neoplasms/genetics ; Central Nervous System Neoplasms/drug therapy ; Protein Kinase Inhibitors/pharmacology
Chemical Substances	ErbB Receptors (EC 2.7.10.1) ; Protein Kinase Inhibitors
Language	English
Publishing date	2024-03-09
Publishing country	England
Document type	Journal Article
ZDB-ID	2615211-3
ISSN	2045-2322 ; 2045-2322
ISSN (online)	2045-2322
ISSN	2045-2322
DOI	10.1038/s41598-024-56046-w
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: First-line treatment of patients with HER2-positive metastatic gastric and gastroesophageal junction cancer.

Aktürk Esen, Selin / Ergun, Yakup / Erol, Cihan / Arikan, Rukiye / Er, Muhammed Muhiddin / Atci, Muhammed Mustafa / Topçu, Atakan / Uçar, Gökhan / Akagündüz, Baran / Aykan, Musa Bariş / Özen, Miraç / Baytemur, Naziyet Köse / Özçelik, Melike / Şahin, Elif / Güven, Denizcan / Menekşe, Serkan / Ak, Naziye / Teker, Fatih / Kut, Engin /

Şakalar, Teoman / Alan, Özkan / Kaçan, Turgut / Turhal, Nazim Serdar / Kiliçkap, Saadettin / Türker, Sema / Şendur, Mehmet Ali Nahit / Köstek, Osman / Karaağaç, Mustafa / Sakin, Abdullah / Türk, Haci Mehmet / Çağlayan, Dilek / Cihan, Şener / Açikgöz, Yusuf / Uncu, Doğan

Bosnian journal of basic medical sciences

2022 Volume 22, Issue 5, Page(s) 818–825

Abstract: Fluoropyrimidine+cisplatin/oxaliplatin+trastuzumab therapy is recommended for the first-line treatment of HER2-positive metastatic gastric adenocarcinoma. However, there is no comprehensive study on which platinum-based treatment should be preferred. ... ...

Abstract	Fluoropyrimidine+cisplatin/oxaliplatin+trastuzumab therapy is recommended for the first-line treatment of HER2-positive metastatic gastric adenocarcinoma. However, there is no comprehensive study on which platinum-based treatment should be preferred. This study aimed to compare the treatment response and survival characteristics of patients with HER2-positive metastatic gastric or gastroesophageal junction (GEJ) cancer who received fluorouracil, oxaliplatin, and leucovorin (mFOLFOX)+trastuzumab or cisplatin and fluorouracil (CF)+trastuzumab as first-line therapy. It was a multicenter, retrospective study of the Turkish Oncology Group, which included 243 patients from 21 oncology centers. There were 113 patients in the mFOLFOX+trastuzumab arm and 130 patients in the CF+trastuzumab arm. The median age was 62 years in the mFOLFOX+trastuzumab arm and 61 years in the CF+trastuzumab arm (P = 0.495). 81.4% of patients in the mFOLFOX+trastuzumab arm and 83.1% in the CF+trastuzumab arm had gastric tumor localization (P = 0.735). The median progression-free survival (PFS) was significantly higher in the mFOLFOX+trastuzumab arm (9.4 months vs. 7.3 months, P = 0.024). The median overall survival (OS) was similar in both groups (18.4 months vs. 15.1 months, P = 0.640). Maintenance trastuzumab was continued after chemotherapy in 101 patients. In this subgroup, the median OS was 23.3 months and the median PFS was 13.3 months. In conclusion, mFOLFOX+trastuzumab is similar to CF+trastuzumab in terms of the median OS, but it is more effective in terms of the median PFS in the first-line treatment of HER2-positive metastatic gastric and GEJ cancer. The choice of treatment should be made by considering the prominent toxicity findings of the chemotherapy regimens.
MeSH term(s)	Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Cisplatin/therapeutic use ; Esophageal Neoplasms/drug therapy ; Esophagogastric Junction/pathology ; Fluorouracil/therapeutic use ; Humans ; Leucovorin/therapeutic use ; Middle Aged ; Oxaliplatin/therapeutic use ; Receptor, ErbB-2 ; Retrospective Studies ; Stomach Neoplasms/pathology ; Trastuzumab/therapeutic use
Chemical Substances	Oxaliplatin (04ZR38536J) ; Receptor, ErbB-2 (EC 2.7.10.1) ; Trastuzumab (P188ANX8CK) ; Cisplatin (Q20Q21Q62J) ; Leucovorin (Q573I9DVLP) ; Fluorouracil (U3P01618RT)
Language	English
Publishing date	2022-09-16
Publishing country	Bosnia and Herzegovina
Document type	Journal Article ; Multicenter Study
ZDB-ID	2240029-1
ISSN	1840-4812 ; 1512-8601
ISSN (online)	1840-4812
ISSN	1512-8601
DOI	10.17305/bjbms.2021.7069
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 6314: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Treatment efficacy of ribociclib or palbociclib plus letrozole in hormone receptor-positive/HER2-negative metastatic breast cancer.

Kahraman, Seda / Erul, Enes / Seyyar, Mustafa / Gumusay, Ozge / Bayram, Ertugrul / Demirel, Burcin Cakan / Acar, Omer / Aksoy, Sercan / Baytemur, Naziyet Kose / Sahin, Elif / Cabuk, Devrim / Basaran, Gul / Paydas, Semra / Yaren, Arzu / Guven, Deniz Can / Erdogan, Atike Pinar / Demirci, Umut / Yasar, Alper / Bayoglu, İbrahim Vedat /

Hizal, Mutlu / Gulbagci, Burcu / Paksoy, Nail / Davarci, Sena Ece / Yilmaz, Funda / Dogan, Ozlem / Orhan, Sibel Oyucu / Kayikcioglu, Erkan / Aytac, Ali / Keskinkilic, Merve / Mocan, Eda Eylemer / Unal, Olcun Umit / Aydin, Esra / Yucel, Hakan / Isik, Deniz / Eren, Onder / Uluc, Basak Oyan / Ozcelik, Melike / Hacibekiroglu, Ilhan / Aydiner, Adnan / Demir, Hacer / Oksuzoglu, Berna / Cilbir, Ebru / Cubukcu, Erdem / Cetin, Bulent / Oktay, Esin / Erol, Cihan / Okutur, Sadi Kerem / Yildirim, Nilgun / Alkan, Ali / Selcukbiricik, Fatih / Aksoy, Asude / Karakas, Yusuf / Ozkanli, Gulhan / Duman, Berna Bozkurt / Aydin, Dincer / Dulgar, Ozgecan / Er, Muhammed Muhiddin / Teker, Fatih / Yavuzsen, Tugba / Aykan, Musa Baris / Inal, Ali / Iriagac, Yakup / Kalkan, Nurhan Onal / Keser, Murat / Sakalar, Teoman / Menekse, Serkan / Kut, Engin / Bilgin, Burak / Karaoglanoglu, Muge / Sunar, Veli / Ozdemir, Ozlem / Turhal, Nazim Serdar / Karadurmus, Nuri / Yalcin, Bulent / Nahit Sendur, Mehmet Ali

Future oncology (London, England)

2023 Volume 19, Issue 10, Page(s) 727–736

Abstract: Background: ...

Abstract	Background:
MeSH term(s)	Humans ; Female ; Letrozole/therapeutic use ; Breast Neoplasms/pathology ; Retrospective Studies ; Aminopyridines/therapeutic use ; Treatment Outcome ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Receptor, ErbB-2
Chemical Substances	Letrozole (7LKK855W8I) ; palbociclib (G9ZF61LE7G) ; ribociclib (TK8ERE8P56) ; Aminopyridines ; Receptor, ErbB-2 (EC 2.7.10.1)
Language	English
Publishing date	2023-05-03
Publishing country	England
Document type	Journal Article
ZDB-ID	2274956-1
ISSN	1744-8301 ; 1479-6694
ISSN (online)	1744-8301
ISSN	1479-6694
DOI	10.2217/fon-2022-1287
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 6478: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

To top

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito